HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target [Yahoo! Finance]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Yahoo! Finance
On December 10, HSBC analyst Rajesh Kumar raised the firm's price target on GSK plc (NYSE:GSK) to 1,500 GBp from 1,200 GBp and kept a Reduce rating on the shares. The move came as part of HSBC's 2026 outlook for the pharmaceutical sector. The firm said the group is positioned to outperform next year, “even more so if AI panic kicks in.” HSBC added that its preferred names sit in the “growth bucket ideas,” though it noted that “fallen angels and value could work as well.” A few days later, on December 16, GSK plc (NYSE:GSK) shared an update on the regulatory front. The US Food and Drug Administration approved the company's add-on treatment for severe asthma, giving patients access to a therapy that requires less frequent dosing. At the same time, the agency declined to approve the drug for another condition. The decision comes as GSK prepares for a leadership transition. Commercial chief Luke Miels is set to step into the CEO role early next year, at a time when the company is d
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSKPR Newswire
- Exdensur (depemokimab) approved by US FDA for the treatment of severe asthmaBusiness Wire
- GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) had its "reduce" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
GSK
Sec Filings
- 12/23/25 - Form 6-K
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- GSK's page on the SEC website